Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Accumulated Expenses (2016 - 2025)

Anaptysbio (ANAB) has disclosed Accumulated Expenses for 8 consecutive years, with $32.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Expenses rose 286.72% year-over-year to $32.7 million, compared with a TTM value of $32.7 million through Dec 2025, up 286.72%, and an annual FY2025 reading of $32.7 million, up 286.72% over the prior year.
  • Accumulated Expenses was $32.7 million for Q4 2025 at Anaptysbio, up from $30.2 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $33.7 million in Q2 2024 and bottomed at $8.4 million in Q4 2024.
  • Average Accumulated Expenses over 4 years is $20.4 million, with a median of $16.7 million recorded in 2022.
  • The sharpest move saw Accumulated Expenses decreased 15.78% in 2021, then skyrocketed 286.72% in 2025.
  • Year by year, Accumulated Expenses stood at $12.9 million in 2021, then surged by 68.31% to $21.6 million in 2022, then plummeted by 60.94% to $8.4 million in 2024, then surged by 286.72% to $32.7 million in 2025.
  • Business Quant data shows Accumulated Expenses for ANAB at $32.7 million in Q4 2025, $30.2 million in Q2 2025, and $8.4 million in Q4 2024.